0218 GMT - Hansoh Pharmaceutical is expected to increase R&D spending in 2026, which should continue to fuel business-development income on a sustained basis, CMB International analysts Jill Wu and Andy Wang say in a note. The brokerage forecasts the company's 2026 revenue to rise 11.1% to 16.81 billion yuan, with net profit increasing 3.6% to 5.77 billion yuan. CMB International raises its target price to HK$46.41 from HK$45.26 while maintaining a buy rating. The stock last traded at HK$39.36. (venkat.pr@wsj.com)
(END) Dow Jones Newswires
April 05, 2026 22:18 ET (02:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments